BRPI0907382A2 - Antagonista de receptor de opioide seletivo capa. - Google Patents

Antagonista de receptor de opioide seletivo capa.

Info

Publication number
BRPI0907382A2
BRPI0907382A2 BRPI0907382-5A BRPI0907382A BRPI0907382A2 BR PI0907382 A2 BRPI0907382 A2 BR PI0907382A2 BR PI0907382 A BRPI0907382 A BR PI0907382A BR PI0907382 A2 BRPI0907382 A2 BR PI0907382A2
Authority
BR
Brazil
Prior art keywords
cloak
receptor antagonist
opioid receptor
selective opioid
selective
Prior art date
Application number
BRPI0907382-5A
Other languages
English (en)
Inventor
Nuria Diaz Buezo
David Lee Mckinzie
Charles Howard Mitch
Concepcion Pedregal-Tercero
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BRPI0907382A2 publication Critical patent/BRPI0907382A2/pt
Publication of BRPI0907382B1 publication Critical patent/BRPI0907382B1/pt
Publication of BRPI0907382B8 publication Critical patent/BRPI0907382B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
BRPI0907382A 2008-01-22 2009-01-13 antagonista de receptor de opioide seletivo capa, seu uso e composição farmacêutica que o compreende BRPI0907382B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP08380012 2008-01-22
EP08380012.8 2008-01-22
US3912108P 2008-03-25 2008-03-25
US61/039,121 2008-03-25
PCT/US2009/030811 WO2009094260A1 (en) 2008-01-22 2009-01-13 Kappa selective opioid receptor antagonist

Publications (3)

Publication Number Publication Date
BRPI0907382A2 true BRPI0907382A2 (pt) 2015-07-21
BRPI0907382B1 BRPI0907382B1 (pt) 2020-03-10
BRPI0907382B8 BRPI0907382B8 (pt) 2021-05-25

Family

ID=40876972

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0907382A BRPI0907382B8 (pt) 2008-01-22 2009-01-13 antagonista de receptor de opioide seletivo capa, seu uso e composição farmacêutica que o compreende

Country Status (32)

Country Link
US (2) US7709522B2 (pt)
EP (1) EP2252581B1 (pt)
JP (1) JP5345637B2 (pt)
KR (1) KR101172170B1 (pt)
CN (1) CN101925576B (pt)
AR (1) AR070158A1 (pt)
AU (1) AU2009206653B2 (pt)
BR (1) BRPI0907382B8 (pt)
CA (1) CA2713025C (pt)
CO (1) CO6290644A2 (pt)
CY (1) CY1113071T1 (pt)
DK (1) DK2252581T3 (pt)
DO (1) DOP2010000222A (pt)
EA (1) EA017484B1 (pt)
EC (1) ECSP10010365A (pt)
ES (1) ES2388708T3 (pt)
HR (1) HRP20120558T1 (pt)
IL (1) IL206038A (pt)
JO (1) JO2797B1 (pt)
MA (1) MA32751B1 (pt)
MX (1) MX2010007849A (pt)
MY (1) MY163014A (pt)
NZ (1) NZ586225A (pt)
PE (1) PE20091317A1 (pt)
PL (1) PL2252581T3 (pt)
PT (1) PT2252581E (pt)
SI (1) SI2252581T1 (pt)
TN (1) TN2010000306A1 (pt)
TW (1) TWI422369B (pt)
UA (1) UA100715C2 (pt)
WO (1) WO2009094260A1 (pt)
ZA (1) ZA201003908B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7709522B2 (en) * 2008-01-22 2010-05-04 Eli Lilly And Company Kappa selective opioid receptor antagonist
EP2240485B1 (en) * 2008-01-22 2014-10-15 Takeda Pharmaceutical Company Limited Tricyclic compounds having corticotropin-releasing factor antagonistic activity and pharmaceutical compositions containing them
EP2757881A4 (en) 2011-09-15 2014-11-12 Univ Kansas KAPPA OPIATE RECEPTOR EFFECTORS AND USES THEREOF
US10813925B2 (en) 2011-09-19 2020-10-27 Carmel—Haifa University Economic Corporation Ltd. Buprenorphine for the treatment of acute suicidality
WO2013086496A2 (en) 2011-12-09 2013-06-13 Research Triangle Institute 1-substituted 4-arylpiperazine as kappa opioid receptor antagonists
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
US9283196B1 (en) 2013-01-30 2016-03-15 MediSynergics, LLC Cycloalkyl-diamines for CNS disorders
ES2770978T3 (es) * 2013-05-24 2020-07-06 Alkermes Pharma Ireland Ltd Análogos de morfanos y morfinanos y métodos de uso
US10316021B2 (en) 2016-11-28 2019-06-11 Pfizer Inc. Heteroarylphenoxy benzamide kappa opioid ligands
DK3596069T3 (da) 2017-03-17 2022-08-01 Scripps Research Inst Kappa-opioid-receptor-antagonister og produkter og fremgangsmåder relateret dertil
JP6480616B1 (ja) 2018-02-08 2019-03-13 有限会社 ディオン光学技研 照準スコープ
US11266627B1 (en) 2021-05-04 2022-03-08 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
CN114195693A (zh) * 2020-09-17 2022-03-18 广东东阳光药业有限公司 一种酰胺化合物的晶型及其制备方法
CN114591211B (zh) * 2020-12-04 2025-10-21 广东东阳光药业股份有限公司 一种酰胺化合物的共晶及其制备方法
CN117615757A (zh) * 2021-05-04 2024-02-27 杨森制药公司 用于治疗抑郁症的组合物和方法
WO2022234457A1 (en) 2021-05-04 2022-11-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
WO2023131920A1 (en) * 2022-01-10 2023-07-13 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
JP2025503649A (ja) * 2022-01-10 2025-02-04 ヤンセン ファーマシューティカルズ，インコーポレーテッド うつ病の治療のための組成物及び方法
CA3254546A1 (en) * 2022-03-07 2023-09-14 Janssen Pharmaceuticals, Inc. COMPOSITIONS CONTAINING ATICAPRANT
EP4489748A1 (en) * 2022-03-07 2025-01-15 Janssen Pharmaceuticals, Inc. Pure forms of crystalline aticaprant
CN119156211A (zh) 2022-03-07 2024-12-17 杨森制药公司 用于治疗重性抑郁障碍的多晶型形式的阿替卡普兰
JP7176142B1 (ja) 2022-03-09 2022-11-21 直迪 清瀬 各アルコール飲用者において飲用し得るアルコール飲料の種類に対応する飲用量の上限値に関する情報を提供するシステム

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457208A (en) 1993-06-21 1995-10-10 Regents Of The University Of Minnesota Kappa opioid receptor antagonists
ES2189759T3 (es) * 1999-05-12 2003-07-16 Hoffmann La Roche Derivados de imidazoiacepina.
US20020052365A1 (en) * 2000-10-05 2002-05-02 Mohler Hanns Selective anxiolytic therapeutic agents
JP2004518654A (ja) 2000-12-21 2004-06-24 ザ マクレーン ホスピタル コーポレーション 鬱病の治療法
US6974824B2 (en) 2001-01-08 2005-12-13 Research Triangle Institute Kappa opioid receptor ligands
WO2003082832A2 (en) * 2002-03-28 2003-10-09 Wisys Technology Foundation, Inc. Anxiolytic agents with reduced sedative and ataxic effects
PT2208727E (pt) 2002-09-19 2012-10-11 Lilly Co Eli Éteres diarílicos como antagonista do receptor opióide
EP1606275B1 (en) 2003-03-07 2008-08-27 Eli Lilly And Company Opioid receptor antagonists
WO2004080968A1 (en) 2003-03-07 2004-09-23 Eli Lilly And Company 6-substituted nicotinamide derivatives as opioid receptor antagonists
CN1890208A (zh) 2003-12-12 2007-01-03 伊莱利利公司 类鸦片受体拮抗剂
BRPI0417714A (pt) 2003-12-22 2007-03-20 Lilly Co Eli composto, composição farmacêutica, e, uso de um composto
JP2007528898A (ja) 2004-03-12 2007-10-18 イーライ リリー アンド カンパニー オピオイド受容体拮抗物質
AU2005222640A1 (en) 2004-03-12 2005-09-29 The Mclean Hospital Corporation Salvinorin derivatives and uses thereof
US7381750B2 (en) 2004-03-12 2008-06-03 Eli Lilly And Company Amino-phenoxymethyl-benzamide opioid receptor antagonists
US7378448B2 (en) 2004-03-15 2008-05-27 Eli Lilly And Company Diphenylether amide derivatives as opioid receptor antagonists
WO2005090303A1 (en) 2004-03-15 2005-09-29 Eli Lilly And Company 4- (5- (aminomethyl) -indole-1-ylmethyl) -benzamide derivatives and related compounds as opioid receptor antagonists for the treatment of obesity
US8551986B2 (en) 2005-12-08 2013-10-08 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
PL2001456T3 (pl) 2006-04-04 2010-05-31 Emodys Gmbh Zastosowanie kompozycji zawierających antagonistę receptora opioidowego kappa do leczenia zaburzeń dysocjacyjnych
US8633175B2 (en) 2006-08-09 2014-01-21 Glaxosmithkline Llc Compounds as antagonists or inverse agonists at opioid receptors
JP2010500372A (ja) 2006-08-09 2010-01-07 スミスクライン ビーチャム コーポレーション オピオイド受容体に対するアンタゴニストまたはインバースアゴニストとしての新規化合物
MX2009002527A (es) 2006-09-08 2009-03-20 Pfizer Prod Inc Derivados de eter diarilico y usos de los mismos.
US7709522B2 (en) * 2008-01-22 2010-05-04 Eli Lilly And Company Kappa selective opioid receptor antagonist

Also Published As

Publication number Publication date
TWI422369B (zh) 2014-01-11
CA2713025C (en) 2012-12-04
DOP2010000222A (es) 2015-11-15
EP2252581A1 (en) 2010-11-24
DK2252581T3 (da) 2012-07-16
SI2252581T1 (sl) 2012-09-28
KR20100095639A (ko) 2010-08-31
IL206038A0 (en) 2010-11-30
BRPI0907382B1 (pt) 2020-03-10
EA017484B1 (ru) 2012-12-28
NZ586225A (en) 2012-05-25
CY1113071T1 (el) 2016-04-13
PL2252581T3 (pl) 2012-10-31
CO6290644A2 (es) 2011-06-20
US20100197669A1 (en) 2010-08-05
IL206038A (en) 2013-11-28
CN101925576A (zh) 2010-12-22
JO2797B1 (en) 2014-03-15
WO2009094260A1 (en) 2009-07-30
MY163014A (en) 2017-07-31
MA32751B1 (fr) 2011-11-01
TW200936129A (en) 2009-09-01
CA2713025A1 (en) 2009-07-30
CN101925576B (zh) 2013-02-06
ECSP10010365A (es) 2010-08-31
ZA201003908B (en) 2011-11-30
JP2011524850A (ja) 2011-09-08
BRPI0907382B8 (pt) 2021-05-25
HRP20120558T1 (hr) 2012-10-31
UA100715C2 (ru) 2013-01-25
AR070158A1 (es) 2010-03-17
AU2009206653A1 (en) 2009-07-30
US7709522B2 (en) 2010-05-04
AU2009206653B2 (en) 2013-07-18
PT2252581E (pt) 2012-08-31
TN2010000306A1 (en) 2011-11-11
HK1146822A1 (en) 2011-07-15
ES2388708T3 (es) 2012-10-17
US8173695B2 (en) 2012-05-08
EA201070877A1 (ru) 2010-12-30
MX2010007849A (es) 2010-08-09
KR101172170B1 (ko) 2012-08-07
JP5345637B2 (ja) 2013-11-20
EP2252581B1 (en) 2012-06-20
PE20091317A1 (es) 2009-09-03
US20090186873A1 (en) 2009-07-23

Similar Documents

Publication Publication Date Title
FR22C1020I2 (fr) Antagonistes de c5ar
DK2252581T3 (da) Kappa-selektiv opioidreceptorantagonist
EP2350060A4 (en) Melanocortin receptor AGONISTS
BRPI0810926A2 (pt) Antagonista de crig
ATE509022T1 (de) Nikotin-acetylcholin-rezeptorsubtyp-selektive diazabicycloalkanamide
PT2315781E (pt) Antagonistas específicos do recetor fgf-r4
BRPI0910118A2 (pt) antagonistas de receptores do glucagon
BRPI1016189A2 (pt) compostos de 4-azetidinil-1-fenil-ciclohexano antagonistas de ccr2
BRPI0919539A2 (pt) antagonistas de receptor de opioide periférico e empregos dos mesmos
BRPI0817245A2 (pt) Derivados e quinolina como antagonistas receptores de 5ht5a
HRP20170246T1 (hr) Režim doziranja za selektivni agonist s1p1-receptora
HRP20151108T1 (xx) Antagonisti nogo-receptora
EP2310574A4 (en) Mobile barrier
SMT201400113B (it) Nalmefene cloridrato diidrato
EP2184278A4 (en) P2X4 RECEIVER ANTAGONIST
BRPI0820805A2 (pt) Antagonista do receptor de mineralocorticóides derivados da 6h-di-benzo[b,e]oxepina
DK2009992T3 (da) Il-8 receptor-antagonister
BRPI0921663A2 (pt) dispositivo de diaplay
BRPI0918004A2 (pt) antagonistas de glucagon
HRP20160950T1 (hr) Polimorfi antagonista mglur5 receptora
BRPI0908008A2 (pt) Farmacóforo dual - pde4-antagonistas muscarínicos
BRPI1013716A2 (pt) 5-alquinil-piridinas.
EP2342320A4 (en) CHINESE hamster ovary-CELL LINES
PL2357183T3 (pl) Związki morfinanu
BR112012005119A2 (pt) novos antagonistas de hepcidina etanodiaminas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/03/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/01/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF